Variable response to growth hormone therapy in growth hormone deficient patients and role of insulin like growth factor one in monitoring response to therapy

Kawes Omer  Zangana; Zaher Taher   Gardi; Dawand Dlshad   Abdulla

doi:10.56056/amj.2017.26

Authors

Kawes Omer Zangana D.C.H, F.I.B.M.S, Assistant prof. in pediatrics,Hawler Medical University, College of Medicine
Zaher Taher Gardi CABP, Pediatrician, Raparin Pediatric Teaching Hospital
Dawand Dlshad Abdulla KBMS, Pediatrician, Raparin Pediatric Teaching Hospital

DOI:

https://doi.org/10.56056/amj.2017.26

Keywords:

Bone age, Growth hormone deficiency, Insulin-like growth factor, Short stature

Abstract

Background and objectives: To find out the response to growth hormone therapy among growth hormone deficiency patients with different causes and to find out the role of insulin-like growth factor one in monitoring response.

Methods: This retrospective study was done on fifty patients who received growth hormone for short stature due to different causes. The patients were enrolled in the study that was conducted from June 2015 to December 2015 in Helina center- Erbil. All details including history, examination, investigations, treatment and follow-up were revised. Investigations that have been sent for each patient were full blood count, thyroid function tests, bone age assessment, growth hormone stimulation and insulin like growth factor one. Follow-up for their response clinically and by investigations have been done after 3, 6 and 12 months and after two years from initiating growth hormone therapy. Patients were divided to three groups, patients on 25 mcg/kg/day therapy (Group One), patient on 30 mcg/kg/day (Group Two) and patients on 35 mcg/kg/day (Group Three). The response to growth hormone therapy of the three groups was compared.

Results: Among those fifty patients, only five patients discontinued their treatment. Significant height gain was observed after two years of regular growth hormone therapy. We found that with increasing the dose of growth hormone, the patient gain more height, and had higher insulin-like growth factor one, with p<0.05 between the groups. The mean height gain over 2 years of growth hormone therapy was 11.16 cm in Group One and 16.25 cm in Group Three. Conclusions: We conclude that by giving growth hormone to short children for a period not less than two years, height will increase significantly. Giving higher allowed doses gives higher increment compared to lower doses and insulin like growth factor one is a good tool for follows-up response to therapy.

Downloads

Download data is not yet available.

References

Cuttler L, Marinova D, Mercer MB. Patient, physician, and consumer drivers: referrals for short stature and access to specialty drugs. Med Care 2009; 47:858.

Cohen P, Rogol AD, Deal CL. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Pediatric Endocrinology Workshop. 2008;93(11):42107-.

Allen DB, Cuttler L. Short Stature in Childhood — Challenges and Choices.2013; 368:12201228-. 4. Rosenfeld RG, Albertsson-Wikland K, Cassorla F. Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J ClinEndocrinolMetab 1995; 80:1532.

Zeitler PS, Sharon HT,.Kristen N, Jennifer MB, Megan MK, Michael SK; Endocrine disorders. In:Hay WW, Levin MJ, Robin R. Deterding RR, Mark j. Abzug MJ, Sondheimer JM. Current diagnosis & treatment of pediatric.21st edition. The McGraw-Hill .2012;1919

Tanner J. Auxology. In: Kappy MS, Blizzard RM, Migeon CJ, eds.The Diagnosis and Treatment of Endocrine Disorders in Childhood and Adolescence. 4th ed. Springfield, IL: Charles C Thomas; 1994; .137192-.

Hall DMB, ed. Health for All Children: Report of the Third Joint Working Party on Child Health Surveillance. 3rd ed. New York, NY: Oxford University Press; 1996

Goldbloom RB, ed. Pediatric Clinical Skills. 2nd ed. New York, NY: Churchill Livingstone; 1997.

Fischbach FT, Dunning MB III, eds. Chemistry Studies. Manual of Laboratory and Diagnostic Tests. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2009;

Scarth JP. «Modulation of the growth hormone-insulin-like growth factor (GH-IGF) axis by pharmaceutical, nutraceutical, and environmental xenobiotics: an emerging role for xenobiotic-metabolizing enzymes and the transcription factors regulating their expression. A review».Xenobiotica 36 (2–3) 2006; 119–218.

Grimberg A, Cohen P.Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesisOptimizing growth hormone therapy. J Cell Physiol. 2000 Apr;183(1):19-

Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 2010;95:167177-.

Yakar S., Liu J.L., Stannard B., Butler A., Accili D., Sauer B., et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc. Nat. Acad. Sci. 1999; 96: 73247329-.

Alatzoglou KS, Dattani MT, Jameson JL, De Groot LJ, de Kretser DM. Growth hormone deficiency in children. Endocrinology: Adult and Pediatric. 7th ed. Philadelphia, PA: Elsevier Saunders; 2015:921.

Rosenbloom AL. The role of recombinant insulin-like growth factor I in the treatment of the short child. Curr.Opin.Pediatr 2007; 19 (4): 458–64.

Stephure DK. Canadian Growth Hormone Advisory Committee. Impact of growth hormone supplementation on adult height in Turner syndrome: Results of the Canadian randomized controlled trial. J ClinEndocrinolMetab. 2005;90:3360–66.

Wit JM, Rekers-Mombarg LT, Cutler GB. Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect. J Pediatr 2005; 146:45.

Blethen SL, Allen DB, Graves D. Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience. J ClinEndocrinolMetab. 1996;81:1704–10.

Cohen P Dose sparing and safety-enhancing effects of an IGF1-based dosing regimen in short children treated with growth hormone in a 2-year randomized control trial: therapeutic and pharmacoeconomic consideration, clinical endocrinology 2014; 81,7176-.

Cohen P, Germak J, Rogol AD. Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children. J ClinEndocrinolMetab 2010; 95:2089.

Cutfield WS, Derraik JG, Gunn AJ. Noncompliance with growth hormone treatment in children is common and impairs linear growth. PLoS One. 2011;6: 16233.